argenx SE (ARGX.BR)
88.90EUR
11 Dec 2018
€0.90 (+1.02%)
€88.00
€88.30
€89.80
€87.90
102,263
123,677
€98.60
€27.72
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | €583.54 |
| Shares Outstanding(Mil.): | 26.89 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARGX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 92.25 | 33.63 |
| EPS (TTM): | -1.07 | -- | -- |
| ROI: | -19.69 | 0.29 | 15.02 |
| ROE: | -19.69 | 0.94 | 16.60 |
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).
AbbVie doubles down on cancer project with biotech group Argenx
BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.
BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod
* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS
Estimates